Patents Represented by Attorney April C. Logan
  • Patent number: 5314813
    Abstract: The present invention relates to a rational, elegant means of producing, loading and using Class I molecules to specifically activate CD8 cells in vitro, and their therapeutic applications in the treatment of a variety of conditions, including cancer, tumors or neoplasias, as well as viral, retroviral, autoimmune, and autoimmune-type diseases. The present invention also relates to vectors, cell lines, recombinant DNA molecules encoding human .beta.2 microglobulin or Class I MHC molecules in soluble and insoluble form, and methods of producing same.
    Type: Grant
    Filed: February 19, 1992
    Date of Patent: May 24, 1994
    Assignee: Scripps Research Institute
    Inventors: Per A. Peterson, Michael Jackson, Pierre Langlade-Demoyen
  • Patent number: 5310874
    Abstract: Diagnostic systems, methods, polypeptides and antibodies for detecting the presence of the cytoplasmic domain of the integrin .alpha..sub.6B or .alpha..sub.
    Type: Grant
    Filed: May 3, 1991
    Date of Patent: May 10, 1994
    Assignee: The Scripps Research Institute
    Inventors: Richard N. Tamura, Vito Quaranta
  • Patent number: 5306620
    Abstract: An integrin-activating antibody is disclosed that immunoreacts with an integrin and when immunoreacted increases the binding affinity of the integrin for binding to ligands specific for the integrin. The antibody also immunoreacts with a ligand-induced binding site (LIBS) on the integrin when the integrin is specifically bound to its ligand. Further disclosed are therapeutic compositions and methods for promoting cell adhesion using the disclosed integrin-activating antibodies.
    Type: Grant
    Filed: November 13, 1990
    Date of Patent: April 26, 1994
    Assignee: The Scripps Research Institute
    Inventors: Mark H. Ginsberg, Timothy E. O'Toole, Edward F. Plow, Andrew L. Frelinger, III
  • Patent number: 5288612
    Abstract: The invention describes diagnostic methods and compositions for determining the amount of protease in a body fluid sample. In particular, the invention detects proteases by a method in which both a reversible inhibitor of the protease and an irreversible inhibitor of interfering proteases during the detection step are employed to increase the sensitivity of the enzyme capture assay. The assay detects normal serum levels of activated protein C.
    Type: Grant
    Filed: July 3, 1991
    Date of Patent: February 22, 1994
    Assignee: The Scripps Research Institute
    Inventors: John H. Griffin, Andras Gruber
  • Patent number: 5284751
    Abstract: An antibody that immunoreacts with a ligand-induced binding site (LIBS) on GPIIIa, and particularly, a LIBS induced in a platelet-associated GPIIb-IIIa/fibrinogen complex is disclosed. Further disclosed are diagnostic systems and methods for assaying LIBS-containing platelets in a vascular fluid sample using the antibodies of the invention.
    Type: Grant
    Filed: October 5, 1989
    Date of Patent: February 8, 1994
    Assignee: The Scripps Research Institute
    Inventors: Andrew L. Frelinger, III, Edward F. Plow, Mark H. Ginsberg
  • Patent number: 5279956
    Abstract: The present invention describes APC polypeptides and anti-peptide antibodies capable of inhibiting activated Protein C anticoagulant activity. The polypeptide and antibody are useful in diagnostic methods and systems for measuring APC in vascular fluid samples. In addition, the polypeptide and anti-peptide antibody are useful in therapeutic methods for inhibiting APC in a human patient.
    Type: Grant
    Filed: June 24, 1991
    Date of Patent: January 18, 1994
    Assignee: The Scripps Research Institute
    Inventors: John H. Griffin, Rolf M. Mesters
  • Patent number: 5271931
    Abstract: The present invention relates to the use of interferon and/or interleukin-6 to increase intravascular C1 inhibitor concentrations in patients exhibiting or at risk for a C1 inhibitor deficiency. Therapeutic compositions containing interferon and/or interleukin-6 are also disclosed.
    Type: Grant
    Filed: September 14, 1988
    Date of Patent: December 21, 1993
    Assignee: The Scripps Research Institute
    Inventors: Martin Lotz, Bruce Zuraw, Dennis A. Carson
  • Patent number: 5266459
    Abstract: A method for detecting a new Gaucher disease mutation in an allele in a human having a point mutation of an adenine nucleotide substituted for a guanine nucleotide at nucleotide position 1 in the normal glucocerebrosidase gene intron 2 is provided. Identification of the mutation is accomplished by first amplifying, with a polymerase chain reaction (PCR) primer, a region of human genomic DNA containing nucleotide position 1 of glucocerebrosidase gene intron 2 followed by detection of the mutation.
    Type: Grant
    Filed: February 24, 1992
    Date of Patent: November 30, 1993
    Assignee: The Scripps Research Institute
    Inventor: Ernest Beutler
  • Patent number: 5262520
    Abstract: Polypeptides derived from the ligand-binding portion of an Integrin alpha subunit are disclosed as are their use for modulation of Integrin ligand binding. Anti-peptide antibodies, hybridomas secreting the antibodies, as well as methods of making and using such antibodies and recombinant DNA molecules coding for the polypeptides are also described. The polypeptides and antibodies to the polypeptides are effective inhibitors of fibrinogen binding to platelets.
    Type: Grant
    Filed: November 29, 1990
    Date of Patent: November 16, 1993
    Assignee: The Scripps Research Institute
    Inventors: Edward F. Plow, Stanley E. D'Souza, Mark H. Ginsberg
  • Patent number: 5260273
    Abstract: A synthetic pulmonary surfactant comprising a pharmaceutically acceptable phospholipid admixed with a polypeptide comprising at least 10 amino acid residues and no more than about 60 amino acid residues, said polypeptide including a sequence having alternating hydrophobic and hydrophilic amino acid residue regions represented by the formula (Z.sub.a U.sub.b).sub.c Z.sub.d, wherein:Z is a hydrophilic amino acid residue independently selected from the group consisting of R and K;U is a hydrophobic amino acid residue independently selected from the group consisting of V, I, L, C, Y and F;a has an average value of about 1 to about 5;b has an average value of about 3 to about 20;c is 1 to 10; andd is 1 to 3;said polypeptide, when admixed with a pharmaceutically acceptable phospholipid, forming a synthetic pulmonary surfactant having a surfactant activity greater than the surfactant activity of the phospholipid alone.
    Type: Grant
    Filed: June 14, 1991
    Date of Patent: November 9, 1993
    Assignee: The Scripps Research Institute
    Inventors: Charles G. Cochrane, Susan D. Revak
  • Patent number: 5244916
    Abstract: The present invention relates to the use of posttranslational modification inhibitors, such as isoprenylation inhibitors, to inhibit activation of phagocyte NADPH oxidase and respiratory burst. Therapeutic compositions containing various inhibitors, and methods of using same, are also disclosed.
    Type: Grant
    Filed: January 31, 1992
    Date of Patent: September 14, 1993
    Assignee: The Scripps Research Institute
    Inventor: Gary M. Bokoch
  • Patent number: 5234811
    Abstract: A method for detecting a new Gaucher disease mutation in an allele in a human having an insertion mutation of a guanine nucleotide adjacent to nucleotide position 57 in the normal glucocerebrosidase gene exon 2 is provided. Identification of the mutation is accomplished by first amplifying, with a polymerase chain reaction (PCR) primer, a region of human genomic DNA containing nucleotide positions 57 and 58 of glucocerebrosidase gene exon 2 followed by detection of the mutation.
    Type: Grant
    Filed: September 27, 1991
    Date of Patent: August 10, 1993
    Assignee: The Scripps Research Institute
    Inventors: Ernest Beutler, Joseph A. Sorge
  • Patent number: 5223610
    Abstract: The present invention contemplates a method of physiologic engineering by genetically altering second messenger levels in cells. This method allows the hyperactivation or inhibition of cell function within cells, tissues and animals by introducing a foreign gene that alters a second messenger system. The use of physiologically engineered animals as systems for determining the effectiveness of therapeutic compositions is also contemplated.
    Type: Grant
    Filed: May 18, 1990
    Date of Patent: June 29, 1993
    Assignee: The Scripps Research Institute
    Inventors: Frank H. Burton, J. Gregor Sutcliffe
  • Patent number: 5202422
    Abstract: The present invention contemplates glycopolypeptide multimers having a polypeptide that contain an immunoglobulin amino acid residue sequence and an oligosaccharide that comprises a core pentasaccharide and N-acetylglucosamine-containing outer branches, such that the multimer is free from sialic acid. The production of passive immunity in an animal by administering a sialic acid free glycopolypeptide multimer is also contemplated. In addition, the invention describes a method for producing a glycopolypeptide multimer by introducing first and second mammalian genes encoding the constituent parts of the multimer into first and second respective members of a plant species, generating a progeny from the first and second plant species members, and isolating the glycopolypeptide multimer from the progeny plant.
    Type: Grant
    Filed: October 2, 1990
    Date of Patent: April 13, 1993
    Assignee: The Scripps Research Institute
    Inventors: Andrew C. Hiatt, Mich B. Hein
  • Patent number: 5200504
    Abstract: The invention contemplates a metallopeptide and a method for producing the metallopeptide. The metallopeptide comprises a polypeptide bonded to a metal cation at two coordinating amino acid residues that are aqueous solvent-accessible, said metallopeptide having a secondary structure stabilized by said bonded metal cation.
    Type: Grant
    Filed: October 2, 1990
    Date of Patent: April 6, 1993
    Assignee: The Scripps Research Institute
    Inventor: Reza M. Ghadiri
  • Patent number: 5196309
    Abstract: Methods are described for characterizing platelet aggregation defects. The defects are characterized as activation, ligand binding, or post-occupancy defects. In one embodiment of the invention a Cam variant of Glanzmann's thrombasthenia is characterized as having a ligand binding defect. In another embodiment, a patient with myelofibrosis is identified as having an activation defect. Rapid analysis are afforded using fluorescence-activated flow cytometry. Also, diagnostic kits are described which comprise antibodies suitable for characterizing the above defects.
    Type: Grant
    Filed: November 15, 1990
    Date of Patent: March 23, 1993
    Assignee: The Scripps Research Institute
    Inventor: Mark H. Ginsberg
  • Patent number: 5183734
    Abstract: Antibodies that immunoreact with the hepatitis B virus HBxAg antigen and with HBxAg polypeptides, as well as diagnostic system and methods for assaying for the presence of HBxAg and anti-HBxAg antibodies in a body sample are disclosed.
    Type: Grant
    Filed: July 17, 1990
    Date of Patent: February 2, 1993
    Assignee: The Scripps Research Institute
    Inventor: Ann M. Moriarty
  • Patent number: 5180806
    Abstract: The present invention relates to polypeptides that immunologically mimic papillomavirus latent proteins and to antibodies and monoclonal antibodies that immunoreact with papillomavirus latent proteins. Systems and methods for detecting the presence and type of papillomavirus in a human subject are also described.
    Type: Grant
    Filed: March 13, 1989
    Date of Patent: January 19, 1993
    Assignee: The Scripps Research Institute
    Inventors: Joakim Dillner, Richard A. Lerner, Richard Smith, D. Elliot Parks
  • Patent number: 5177188
    Abstract: A polypeptide consisting essentially of an amino acid residue sequence selected from the group consisting of:Tyr-His-Asp-Arg-Lys-Glu-Phe-Ala-Lys-Phe-Glu-Glu-Glu-Arg-Ala- Arg-Ala-Lys-Trp-Asp-Thr-Ala-Asn-Asn; SEQ ID No 1 andAla-Asn-Asn-Pro-Leu-Tyr-Lys-Glu-Ala-Thr- Ser-Thr-Phe-Thr-Asn-Ile-Thr-Tyr-Arg-Gly-Thr, SEQ ID No 2.
    Type: Grant
    Filed: December 3, 1990
    Date of Patent: January 5, 1993
    Assignee: The Scripps Research Institute
    Inventors: Mark H. Ginsberg, Robert McMillan, Edward F. Plow
  • Patent number: 5176998
    Abstract: The present invention provides a method for assaying a sample of cells for the presence of a cell surface antigen. More particularly, the present invention describes methods for detecting the presence of plasma and cell bound autoantibodies against cell surface antigens. In addition, the present invention provides a method of crossmatching donor platelets and transfusion recipients.
    Type: Grant
    Filed: November 24, 1987
    Date of Patent: January 5, 1993
    Assignee: The Scripps Research Institute
    Inventor: Robert McMillan